Global HealthPharmaceutical Regulations in Japan

United Nations High Level Panel (UNHLP)

UN Secretary-General Ban Ki-Moon convened a High-Level panel to review and assess proposals and recommend solutions for remedying the policy incoherence between the justifiable rights of inventors, international human rights law, trade rules and public health in the context of health technologies.
In response to the launch of UN HLP, IFPMA submitted 3 contribution to UN HLP.
In its submissions to the HLP, the biopharmaceutical industry provided evidence on the value of intellectual property for access to medicines, as well as workable solutions to create improved access to medicines. Addressing these real and most common barriers, in the pursuit of universal health coverage, requires collaborative efforts and innovative solutions, which are both workable in the long term and practically implementable.

Page Top

  • Office of Pharmaceutical Industry Research(OPIR)
  • Global Health
  • Stop AMR
  • APAC